Drug Search Results
More Filters [+]

Delanzomib

Alternative Names: delanzomib, cep-18770, cep 18770, cep18770
Latest Update: 2024-01-29
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Proteasome Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Delanzomib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Myeloma

Phase 1: Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

C18770/2049

P2

Completed

Multiple Myeloma

2013-03-14

2009-013778-41

P2

Completed

Multiple Myeloma

2012-11-15

C18770/2043

P2

Terminated

Multiple Myeloma

2012-11-01

E-CEP\I\01

P1

Completed

Lymphoma, Non-Hodgkin

2010-03-01

Recent News Events